MRNA vaccine takes on liver cancer in tiny early trial

NCT ID NCT07053072

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see if the vaccine helps control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 mRNA LNP vaccine
What this could lead to: If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 9 people, so it is mainly checking safety. The vaccine may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CANCER

Contacts and locations

Locations

Sichuan University West China Hospital
RECRUITING

Chengdu, Sichuan, China
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.